Emerson Poynter LLP

Emerson Poynter announces that a class action has been filed on behalf of shareholders in the United States District Court for the Southern District of Texas on behalf of purchasers of Encysive Pharmaceuticals Inc. ("Encysive") (NASDAQ:ENCY - News) publicly traded securities during the period between February 19, 2004 and March 24, 2006 (the "Class Period").

The complaint charges Encysive and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Encysive is a biopharmaceutical company focused on the discovery, development and commercialization of different synthetic small molecule compounds for the treatment of a range of cardiovascular, vascular and related inflammatory diseases.

The complaint alleges that throughout the Class Period Encysive made false and misleading statements regarding the success of Sitaxentan, or Thelin, a drug it was developing to treat Pulmonary Arterial Hypertension ("PAH"), and stated that it had completed Phase III development of Thelin. During the Class Period, defendants led shareholders and analysts to believe that FDA approval was imminent and that such approval would make Thelin a competitor to Acetelion Ltd.'s similar drug, Tracleer (Bosentan). However, after the Company completed two successful public offerings and the individual defendants received cash/stock awards based on the apparent success of Thelin, the Company's shareholders learned that defendants had been less than forthcoming with the true prospects for Thelin. On March 27, 2006, U.S. regulators delayed approving Thelin until they could get more data. The FDA sent the Company a letter asking for information and possibly more studies to determine if Thelin was safe and effective for use in treating PAH. On this news, Encysive shares fell 49%

Register your Securities Complaint

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible class action lawsuit. Please click here and fill out the form and we will have a lawyer review your securities complaint.

By submitting this form, you are asking our lawyers to contact you. You are under no obligation to accept their services and you are free to choose which lawyer you want to work with. Lawyers are usually paid out of the proceeds of the settlement or verdict rendered.

At Emerson Poynter, it is our goal to keep you informed about important legal cases and settlements. We are dedicated to helping you resolve your legal complaints.